P|49 A study of first|line treatments for patients with BRAFV600E ...

P-49 A study of first-line treatments for patients with BRAFV600E ...

This is the first study assessing the management of BRAFV600E-mutated mCRC patients in routine clinical practice in Europe.

Real-world first-line treatment of patients with BRAFV600E-mutant ...

The recent phase II FIRE-4.5 study, which assessed FOLFOXIRI plus bevacizumab versus FOLFOXIRI plus cetuximab as first-line treatment for BRAFV600E-mutant mCRC, ...

CAPSTAN - Annals of Oncology

P-49. A study of first-line treatments for patients with BRAFV600E mutant metastatic colorectal cancer in a real-life setting: CAPSTAN study. E. Martinelli1 ...

Real-world first-line treatment of patients with BRAF V600E -mutant ...

This study is, to date, the largest real-world analysis of patients with BRAF V600E -mutant mCRC, providing valuable insights into routine ...

Treatment of patients with BRAF V600E -mutated metastatic ...

Our real-world data suggest that TT should be initiated as soon as possible after the failure of first-line treatment in BRAFV600E-mutated mCRC.

Review Management of BRAF-mutant metastatic colorectal cancer

Following progression of BRAF V600E-mutated mCRC after first-line treatment, subsequent systemic therapy recommendations from the NCCN include the combination ...

The Evolving Treatment Landscape in BRAF-V600E–Mutated ...

Novel approaches for managing BRAF-V600E metastatic colorectal cancer include combinations of BRAF inhibitors and anti-EGFR antibodies with immune checkpoint ...

BRAF v600E–mutant cancers treated with vemurafenib alone or in ...

Patients naïve to prior BRAF inhibitors had statistically significantly improved OS at 12.6 months compared to 10.4 months in the BRAF therapy ...

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated ...

In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E–mutated metastatic colorectal cancer who had had disease progression ...

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients ...

... first-line treatment of patients with BRAF V600–mutant melanoma. Results from a recent phase II study in patients with BRAF V600E–mutant mCRC who ...

Phase IB Study of Vemurafenib in Combination with Irinotecan and ...

Vemurafenib plus irinotecan and cetuximab was generally well tolerated and achieved a 35% response rate in patients with BRAFV600E metastatic colorectal.

mutant metastatic NSCLC: disease overview and treatment landscape

In a study evaluating dabrafenib plus trametinib for BRAFV600E-mutant metastatic NSCLC, patients with a concurrent mutation in the PI3K pathway ...

Treatment of metastatic colorectal cancer with BRAF V600E mutation

However, the optimal first-line treatment for BRAF V600E-mutated mCRC patients is still controversial. In the TRIBE study, 508 patients with untreated mCRC ...

Real‐world treatment and outcomes of patients with metastatic ...

Nevertheless, the BRAF V600E mutation retained the negative effect on first line PFS (p = 0.003) and OS (p = 0.042) after multivariate survival ...

Improved Survival with Vemurafenib in Melanoma with BRAF V600E ...

A phase 2 trial involving patients who had received previous treatment for melanoma with the BRAF V600E mutation showed a confirmed response ...

ESMO 2014: Combination Dabrafenib/Trametinib Improves OS in ...

First-line treatment with combination therapy dabrafenib plus trametinib improves overall survival (OS) in comparison with vemurafenib in ...

Safety and efficacy of encorafenib–cetuximab combination in BRAF ...

This retrospective study included BRAFV600E-mutated mCRC patients treated in second line with EC in the RW setting. The primary endpoint (EC ...

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF ...

... patients with a single BRAF V600E mutation (p ... therapies for first-line treatment of patients with NSCLC harboring oncogenic driver mutations.

Clinical Trials Using Trametinib - NCI

This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic ...

The effect of BRAF V600E mutation on survival and treatment ...

These patients rather should receive first-line ... study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.